Pre­ci­sion Bio wants to show there's a bet­ter way to ed­it genes — and now it has $126M in IPO cash to prove it

Af­ter spend­ing the sec­ond half of last year lay­ing the car­pet for an IPO — com­plete with a crossover round and a big part­ner­ship with Gilead — Pre­ci­sion Bio­Sciences has raised $126 mil­lion in its pub­lic de­but.

The go­ing price was $16 each for 7.9 mil­lion shares $DTIL, smack in the mid­dle of its pro­posed range but land­ing above Pre­ci­sion’s orig­i­nal pen­cilled-in goal of $100 mil­lion.

The Durham, NC-based gene edit­ing up­start is pitch­ing its ARC nu­cle­ase ap­proach as a bet­ter al­ter­na­tive to the promi­nent trio of CRISPR, TAL­EN and zinc fin­ger nu­cle­ase. Dubbed AR­CUS, the tech de­rives its name from a hom­ing en­donu­cle­ase found in al­gae called I-Crel, re­pur­pos­ing its nat­ur­al genome edit­ing abil­i­ties to cut and paste on­to cells as need­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA